First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study

M. Steven Piver, Sharad A Ghamande, Gamal H. Eltabbakh, Catherine O'Neill-Coppola

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective. The aim of this study was to assess the role of first-line chemotherapy with paclitaxel and platinum in the treatment of advanced or recurrent cervix cancer. Methods. Twenty patients with advanced or recurrent cancer of the cervix with no prior chemotherapy and measurable disease were entered in a phase II trial from September 1995 to September 1998. Seventeen patients were treated with paclitaxel at 135 mg/m2 over 24 h followed by cisplatin at 75 mg/m2 every 4 weeks. Three patients with impaired renal function were treated with paclitaxel at 135 mg/m2 over 3 h with carboplatin at 300 mg/m2. Results. A clinical response rate of 45% was noted (two complete responses and seven partial responses) with a median duration of 6 months (range: 1.5-9). The median progression-free interval and overall survival in patients with a clinical response was 10.5 and 13 months, respectively, compared to 4 (P = 0.015) and 6 months in the nonresponders (P = 0.14). Seven of nine patients (77.8%) with a clinical response are alive. Patients with recurrences outside the radiation field had twice the response rate (60%) than that of those within the radiated field. The chemotherapy was well tolerated; the most significant toxicity was grade 3/4 neutropenia (55%). No patient had discontinuation of chemotherapy due to toxicity. Conclusions. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cervix cancer is promising and deserves consideration for large phase III trials.

Original languageEnglish (US)
Pages (from-to)334-337
Number of pages4
JournalGynecologic Oncology
Volume75
Issue number3
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Paclitaxel
Platinum
Uterine Cervical Neoplasms
Drug Therapy
Carboplatin
Neutropenia
Cisplatin
Radiation
Kidney
Recurrence
Survival

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study. / Piver, M. Steven; Ghamande, Sharad A; Eltabbakh, Gamal H.; O'Neill-Coppola, Catherine.

In: Gynecologic Oncology, Vol. 75, No. 3, 01.01.1999, p. 334-337.

Research output: Contribution to journalArticle

Piver, M. Steven ; Ghamande, Sharad A ; Eltabbakh, Gamal H. ; O'Neill-Coppola, Catherine. / First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study. In: Gynecologic Oncology. 1999 ; Vol. 75, No. 3. pp. 334-337.
@article{9191bed6da5142ca96d6e0673e0d09a2,
title = "First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study",
abstract = "Objective. The aim of this study was to assess the role of first-line chemotherapy with paclitaxel and platinum in the treatment of advanced or recurrent cervix cancer. Methods. Twenty patients with advanced or recurrent cancer of the cervix with no prior chemotherapy and measurable disease were entered in a phase II trial from September 1995 to September 1998. Seventeen patients were treated with paclitaxel at 135 mg/m2 over 24 h followed by cisplatin at 75 mg/m2 every 4 weeks. Three patients with impaired renal function were treated with paclitaxel at 135 mg/m2 over 3 h with carboplatin at 300 mg/m2. Results. A clinical response rate of 45{\%} was noted (two complete responses and seven partial responses) with a median duration of 6 months (range: 1.5-9). The median progression-free interval and overall survival in patients with a clinical response was 10.5 and 13 months, respectively, compared to 4 (P = 0.015) and 6 months in the nonresponders (P = 0.14). Seven of nine patients (77.8{\%}) with a clinical response are alive. Patients with recurrences outside the radiation field had twice the response rate (60{\%}) than that of those within the radiated field. The chemotherapy was well tolerated; the most significant toxicity was grade 3/4 neutropenia (55{\%}). No patient had discontinuation of chemotherapy due to toxicity. Conclusions. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cervix cancer is promising and deserves consideration for large phase III trials.",
author = "Piver, {M. Steven} and Ghamande, {Sharad A} and Eltabbakh, {Gamal H.} and Catherine O'Neill-Coppola",
year = "1999",
month = "1",
day = "1",
doi = "10.1006/gyno.1999.5586",
language = "English (US)",
volume = "75",
pages = "334--337",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study

AU - Piver, M. Steven

AU - Ghamande, Sharad A

AU - Eltabbakh, Gamal H.

AU - O'Neill-Coppola, Catherine

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Objective. The aim of this study was to assess the role of first-line chemotherapy with paclitaxel and platinum in the treatment of advanced or recurrent cervix cancer. Methods. Twenty patients with advanced or recurrent cancer of the cervix with no prior chemotherapy and measurable disease were entered in a phase II trial from September 1995 to September 1998. Seventeen patients were treated with paclitaxel at 135 mg/m2 over 24 h followed by cisplatin at 75 mg/m2 every 4 weeks. Three patients with impaired renal function were treated with paclitaxel at 135 mg/m2 over 3 h with carboplatin at 300 mg/m2. Results. A clinical response rate of 45% was noted (two complete responses and seven partial responses) with a median duration of 6 months (range: 1.5-9). The median progression-free interval and overall survival in patients with a clinical response was 10.5 and 13 months, respectively, compared to 4 (P = 0.015) and 6 months in the nonresponders (P = 0.14). Seven of nine patients (77.8%) with a clinical response are alive. Patients with recurrences outside the radiation field had twice the response rate (60%) than that of those within the radiated field. The chemotherapy was well tolerated; the most significant toxicity was grade 3/4 neutropenia (55%). No patient had discontinuation of chemotherapy due to toxicity. Conclusions. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cervix cancer is promising and deserves consideration for large phase III trials.

AB - Objective. The aim of this study was to assess the role of first-line chemotherapy with paclitaxel and platinum in the treatment of advanced or recurrent cervix cancer. Methods. Twenty patients with advanced or recurrent cancer of the cervix with no prior chemotherapy and measurable disease were entered in a phase II trial from September 1995 to September 1998. Seventeen patients were treated with paclitaxel at 135 mg/m2 over 24 h followed by cisplatin at 75 mg/m2 every 4 weeks. Three patients with impaired renal function were treated with paclitaxel at 135 mg/m2 over 3 h with carboplatin at 300 mg/m2. Results. A clinical response rate of 45% was noted (two complete responses and seven partial responses) with a median duration of 6 months (range: 1.5-9). The median progression-free interval and overall survival in patients with a clinical response was 10.5 and 13 months, respectively, compared to 4 (P = 0.015) and 6 months in the nonresponders (P = 0.14). Seven of nine patients (77.8%) with a clinical response are alive. Patients with recurrences outside the radiation field had twice the response rate (60%) than that of those within the radiated field. The chemotherapy was well tolerated; the most significant toxicity was grade 3/4 neutropenia (55%). No patient had discontinuation of chemotherapy due to toxicity. Conclusions. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cervix cancer is promising and deserves consideration for large phase III trials.

UR - http://www.scopus.com/inward/record.url?scp=0032779057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032779057&partnerID=8YFLogxK

U2 - 10.1006/gyno.1999.5586

DO - 10.1006/gyno.1999.5586

M3 - Article

VL - 75

SP - 334

EP - 337

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -